Share This Page
Suppliers and packagers for arranon
✉ Email this page to a colleague
arranon
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sandoz | ARRANON | nelarabine | INJECTABLE;INTRAVENOUS | 021877 | NDA | Novartis Pharmaceuticals Corporation | 0078-0683-61 | 50 mL in 1 VIAL (0078-0683-61) | 2016-10-05 |
| Sandoz | ARRANON | nelarabine | INJECTABLE;INTRAVENOUS | 021877 | NDA | Sandoz Inc | 66758-165-94 | 1 VIAL in 1 CARTON (66758-165-94) / 50 mL in 1 VIAL | 2016-10-05 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ARRANON (nelarabine) API Manufacturing Suppliers
This report identifies key suppliers for the Active Pharmaceutical Ingredient (API) of ARRANON (nelarabine). It details their manufacturing capabilities, regulatory standing, and potential supply chain risks.
Who Manufactures Nelarabine API?
The primary manufacturers of nelarabine API are specialized chemical synthesis companies. These entities often operate under strict Good Manufacturing Practices (GMP) to meet the quality standards required for pharmaceutical production. The landscape of API manufacturing is competitive, with companies vying for contracts based on cost, quality, reliability, and regulatory compliance.
Key Suppliers and Their Capabilities
Several companies possess the technical expertise and infrastructure to produce nelarabine API. These suppliers may operate independently or as contract manufacturing organizations (CMOs) for larger pharmaceutical firms.
- Lonza Group AG: A significant player in API manufacturing, Lonza has a broad portfolio of chemical synthesis capabilities. Their facilities are equipped to handle complex multi-step synthesis and are subject to stringent regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Lonza's involvement in nelarabine API production would likely stem from direct contracts with the innovator or generic drug manufacturers.
- WuXi AppTec: This global pharmaceutical and medical device open-access capability and technology platform company offers comprehensive R&D and manufacturing services, including API production. WuXi AppTec operates multiple GMP-compliant facilities in China and the United States. Their ability to scale production and navigate complex regulatory environments makes them a potential supplier for nelarabine.
- Piramal Pharma Solutions: Piramal is a leading provider of pharmaceutical services, including contract development and manufacturing (CDMO). They have a strong presence in the synthesis of complex molecules. Their global network of manufacturing sites adheres to international GMP standards, positioning them as a viable supplier for nelarabine API.
- Hospira, Inc. (a Pfizer company): While primarily known for its finished dosage forms, Hospira, through its parent company Pfizer, has extensive API manufacturing capabilities. Pfizer's global manufacturing network is accustomed to producing a wide range of complex pharmaceuticals, including oncology drugs. If Pfizer produces a generic version of nelarabine, its internal API manufacturing would be a primary source.
- Granules India Ltd.: Granules India is an established manufacturer of APIs and pharmaceutical intermediates. They have a strong focus on regulated markets and possess the GMP certifications necessary for supplying APIs to the US and European markets. Their expertise in heterocyclic chemistry could be applicable to nelarabine synthesis.
The selection of a specific supplier is contingent on factors such as production volume requirements, cost targets, intellectual property considerations, and the need for specialized chemical synthesis expertise.
Regulatory and Quality Considerations
The manufacturing of nelarabine API is subject to rigorous regulatory scrutiny. Compliance with GMP is paramount to ensure product safety, efficacy, and consistency.
GMP Compliance
- FDA Oversight: Manufacturers supplying the U.S. market must comply with FDA regulations, including 21 CFR Part 210 and 211. Facilities undergo regular inspections to verify adherence to these standards.
- EMA Oversight: Suppliers for the European Union market must meet EMA guidelines, which are largely harmonized with those of the FDA.
- ICH Guidelines: International Council for Harmonisation (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), provide a global standard for API manufacturing.
Drug Master Files (DMFs)
API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about the manufacturing, processing, packaging, and storage of the API. The FDA reviews the relevant sections of a DMF when assessing a drug product application. This allows for the protection of proprietary manufacturing information while providing regulatory bodies with the necessary data for product approval.
Impurity Profiling and Control
A critical aspect of API manufacturing is the control of impurities. Nelarabine, being a purine nucleoside analog, requires precise synthesis to minimize the formation of related substances and genotoxic impurities. Analytical methods for detecting and quantifying these impurities must be validated according to ICH Q2 guidelines.
Supply Chain Dynamics and Potential Risks
The global nature of pharmaceutical API manufacturing introduces several potential risks that can impact supply continuity.
Geographic Concentration
A significant portion of global API manufacturing, including complex intermediates, is concentrated in certain regions, particularly China and India. This concentration can create vulnerabilities to localized events such as:
- Geopolitical Instability: Trade disputes, sanctions, or political unrest in key manufacturing regions can disrupt supply chains.
- Environmental Regulations: Increasingly stringent environmental regulations in manufacturing countries can lead to temporary plant shutdowns for compliance.
- Natural Disasters: Earthquakes, floods, or pandemics can directly impact manufacturing operations.
Raw Material Sourcing
The synthesis of nelarabine involves multiple chemical steps, each requiring specific raw materials and intermediates. Disruptions in the supply of these upstream materials, often sourced from different global suppliers, can cascade and affect the availability of the final API.
Intellectual Property (IP)
While ARRANON (nelarabine) has been approved for some time, the specific manufacturing processes employed by different suppliers may be subject to various patents. Generic manufacturers must ensure their processes do not infringe on existing IP or obtain necessary licenses. This can influence the choice of CMO and the geographical location of manufacturing.
Lead Times and Capacity
The production of complex APIs like nelarabine can involve long lead times, from raw material procurement to final product release. API manufacturers operate with defined capacity. Sudden increases in demand, or the need to switch suppliers, can lead to extended lead times if available capacity is constrained.
Quality Incidents and Recalls
Any quality deviation or recall of a specific API batch can have a profound impact on drug product availability. Manufacturers with robust quality management systems and a history of good compliance are generally preferred.
ARRANON (Nelarabine) - API Specifics
Nelarabine is a prodrug of arabinosylguanine (ara-G). Its chemical structure is 9-β-D-arabinofuranosylguanine. The synthesis is a multi-step process involving purine chemistry and sugar moiety attachment.
Key Synthesis Challenges
- Stereoselectivity: Ensuring the correct β-anomer configuration of the arabinofuranosyl moiety is critical for biological activity.
- Functional Group Protection/Deprotection: Managing reactive functional groups on both the purine base and the sugar is essential for selective reactions.
- Purification: Achieving high purity required for pharmaceutical use necessitates efficient purification techniques, such as chromatography and crystallization.
Potential Impact of Generic Competition
The patent landscape for ARRANON has evolved, creating opportunities for generic manufacturers. The entry of generic competition typically leads to:
- Increased Demand for API: As more companies enter the market with generic versions, the overall demand for nelarabine API increases.
- Price Pressure: Generic competition intensifies price negotiations with API suppliers, driving down costs.
- Diversification of Suppliers: To mitigate risks and secure competitive pricing, generic manufacturers often seek to qualify multiple API suppliers.
Comparative Analysis of Potential Suppliers
The following table provides a comparative overview of the identified potential suppliers based on publicly available information and general industry standing. Specific contractual details, pricing, and current capacity are proprietary.
| Supplier | Geographic Presence (Manufacturing) | Regulatory Approvals (Typical) | Key Strengths | Potential Weaknesses |
|---|---|---|---|---|
| Lonza Group AG | Switzerland, USA, UK, Singapore | FDA, EMA, PMDA | Extensive experience, broad technological base | Potentially higher cost due to premium services |
| WuXi AppTec | China, USA | FDA, EMA | Scalability, integrated services, competitive pricing | Geopolitical considerations for some clients |
| Piramal Pharma Solutions | India, USA, UK, Germany | FDA, EMA | CDMO expertise, complex synthesis capability | Dependence on specific regional factors |
| Pfizer (Hospira) | Global | FDA, EMA, Global | Large-scale integrated operations, quality systems | Internal focus may prioritize Pfizer products |
| Granules India Ltd. | India | FDA, EMA | Strong GMP compliance, cost-effectiveness | Capacity for highly complex niche molecules may vary |
Key Takeaways
- Nelarabine API manufacturing is a specialized process requiring significant chemical synthesis expertise and adherence to stringent GMP regulations.
- Key suppliers include global CDMOs and integrated pharmaceutical manufacturers with established track records in regulated markets.
- Supply chain risks are inherent due to geographic concentration, raw material dependencies, and regulatory compliance requirements.
- Generic entry increases demand for nelarabine API and intensifies price competition among suppliers.
- Thorough due diligence on supplier quality systems, regulatory history, and manufacturing capacity is essential for securing a reliable API supply.
Frequently Asked Questions
What are the primary challenges in synthesizing nelarabine API?
The primary challenges include achieving stereoselectivity for the β-anomer, managing reactive functional groups during multi-step synthesis, and ensuring high purity through effective purification techniques.
Which regulatory bodies oversee nelarabine API manufacturing?
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee nelarabine API manufacturing, along with adherence to International Council for Harmonisation (ICH) guidelines.
How does the entry of generic nelarabine affect API suppliers?
The entry of generic nelarabine typically leads to an increased overall demand for the API, heightened price competition among suppliers, and a tendency for generic manufacturers to qualify multiple API sources to ensure supply chain robustness and cost efficiency.
What is a Drug Master File (DMF) in the context of API supply?
A Drug Master File (DMF) is a submission to regulatory authorities containing confidential, detailed information about the manufacturing, processing, packaging, and storage of an API. It allows regulatory bodies to review this proprietary information without public disclosure.
How can a pharmaceutical company mitigate risks associated with nelarabine API supply?
Mitigation strategies include qualifying multiple API suppliers across different geographic regions, establishing strong relationships with suppliers, conducting regular audits, and securing long-term supply agreements that address quality and delivery commitments.
[1] U.S. Food & Drug Administration. (n.d.). 21 CFR Part 210. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPART/314.CFM?ID=210 [2] U.S. Food & Drug Administration. (n.d.). 21 CFR Part 211. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPART/314.CFM?ID=211 [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1998). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q2(R1): Validation of Analytical Procedures: Text and Methodology. [5] Lonza Group AG. (n.d.). API Development and Manufacturing. Retrieved from https://www.lonza.com/services/drug-substance/api-development-and-manufacturing [6] WuXi AppTec. (n.d.). API Manufacturing. Retrieved from https://www.wuxiapptec.com/services/drug-manufacturing/api-manufacturing [7] Piramal Pharma Solutions. (n.d.). API Services. Retrieved from https://www.piramalpharmasolutions.com/api-services [8] Pfizer Inc. (n.d.). Manufacturing & Supply Chain. Retrieved from https://www.pfizer.com/about/operations/manufacturing-supply-chain [9] Granules India Ltd. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from https://www.granulesindia.com/api
More… ↓
